Ratings by UBS (Michael Yee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/28/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 8/20/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 8/20/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/10/2026 | First Tracks Biotherapeutics | TRAX | Maintain | Buy (Buy) |
|
Details | ||
| 8/7/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (Buy) |
|
Details | ||
| 8/5/2026 | Amgen | AMGN | Maintain | Buy (Buy) |
|
Details | ||
| 7/30/2026 | Biogen | BIIB | Maintain | Buy (Buy) |
|
Details | ||
| 7/17/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 7/6/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 7/1/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 6/29/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (Buy) |
|
Details | ||
| 6/23/2026 | Apogee Therapeutics Inc | APGE | Downgrade | Neutral (Buy) |
90.38 (135.08) |
49.46% | Details | |
| 6/16/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (Buy) |
|
Details | ||
| 6/15/2026 | Jade Biosciences | JBIO | New Coverage | Buy (N/A) |
16.08 (21.02) |
30.72% | Details | |
| 6/9/2026 | Revolution | RVMD | Maintain | Buy (Buy) |
|
Details | ||
| 5/28/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 5/27/2026 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/26/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/13/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 5/4/2026 | Moderna | MRNA | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/28/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 4/22/2026 | Biogen | BIIB | Upgrade | Buy (Neutral) |
183.34 (216.04) |
17.84% | Details | |
| 4/21/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 4/21/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Buy (N/A) |
26.93 (41.17) |
52.88% | Details | |
| 4/20/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 4/13/2026 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/13/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Oruka Therapeutics | ORKA | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 3/27/2026 | Kodiak Sciences Inc. | KOD | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 3/17/2026 | Schrodinger | SDGR | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/17/2026 | AnaptysBio | ANAB | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (Buy) |
|
Details | ||
| 3/3/2026 | Nuvation Bio Inc | NUVB | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/27/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
103.24 (209.87) |
103.28% | Details | |
| 2/25/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | MBX Biosciences Inc | MBX | Maintain | Buy (Buy) |
|
Details | ||
| 2/24/2026 | Arcellx Inc. | ACLX | Downgrade | Neutral (Buy) |
64.11 (115.07) |
79.49% | Details | |
| 2/18/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | New Coverage | Buy (N/A) |
29.12 (28.69) |
-1.48% | Details | |
| 2/10/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/2/2026 | Eli Lilly | LLY | Maintain | Buy (Buy) |
|
Details | ||
| 1/15/2026 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 1/13/2026 | Abbvie | ABBV | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/12/2026 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 1/12/2026 | AnaptysBio | ANAB | Maintain | Buy (Buy) |
|
Details | ||
| 1/8/2026 | Ventyx Biosciences Inc | VTYX | Downgrade | Neutral (Buy) |
10.05 (14.00) |
39.3% | Details | |
| 1/7/2026 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
220.18 (259.99) |
18.08% | Details | |
| 1/7/2026 | Biogen | BIIB | New Coverage | Neutral (N/A) |
174.63 (183.34) |
4.99% | Details | |
| 1/7/2026 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (Neutral) |
53.06 (66.92) |
26.12% | Details | |
| 1/7/2026 | Gilead Sciences | GILD | New Coverage | Buy (Neutral) |
118.30 (149.92) |
26.73% | Details | |
| 1/7/2026 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
1041.51 (1160.00) |
11.38% | Details | |
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Buy (N/A) |
77.51 (90.38) |
16.6% | Details | |
| 1/7/2026 | Allogene | ALLO | New Coverage | Buy (N/A) |
1.35 (1.99) |
47.41% | Details | |
| 1/7/2026 | Zai Lab | ZLAB | New Coverage | Buy (N/A) |
18.09 (25.30) |
39.86% | Details | |
| 1/7/2026 | Ventyx Biosciences Inc | VTYX | New Coverage | Buy (N/A) |
7.82 (10.05) |
28.52% | Details | |
| 1/7/2026 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
30.20 (23.03) |
-23.74% | Details | |
| 1/7/2026 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
42.76 (55.89) |
30.71% | Details | |
| 1/7/2026 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
18.50 (18.46) |
-0.22% | Details | |
| 1/7/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.74 (3.70) |
-1.07% | Details | |
| 1/7/2026 | Oruka Therapeutics | ORKA | New Coverage | Buy (N/A) |
26.88 (92.11) |
242.67% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
25.10 (10.56) |
-57.93% | Details | |
| 1/7/2026 | Nuvation Bio Inc | NUVB | New Coverage | Neutral (N/A) |
8.59 (6.64) |
-22.7% | Details | |
| 1/7/2026 | MBX Biosciences Inc | MBX | New Coverage | Buy (N/A) |
29.31 (60.93) |
107.88% | Details | |
| 1/7/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
25.00 (37.06) |
48.24% | Details | |
| 1/7/2026 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
4.60 (4.77) |
3.7% | Details | |
| 1/7/2026 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
32.75 (36.86) |
12.55% | Details | |
| 1/7/2026 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
34.94 (39.95) |
14.34% | Details | |
| 1/7/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
16.02 (23.27) |
45.26% | Details | |
| 1/7/2026 | Cogent | COGT | New Coverage | Buy (N/A) |
34.26 (34.68) |
1.23% | Details | |
| 1/7/2026 | Beam Therapeutics Inc | BEAM | New Coverage | Neutral (N/A) |
26.84 (29.02) |
8.12% | Details | |
| 1/7/2026 | AnaptysBio | ANAB | New Coverage | Buy (N/A) |
43.20 (55.28) |
27.96% | Details | |
| 1/7/2026 | Aligos Therapeutics Inc. | ALGS | New Coverage | Buy (N/A) |
8.41 (6.09) |
-27.59% | Details | |
| 1/7/2026 | Arcellx Inc. | ACLX | New Coverage | Buy (N/A) |
61.83 (64.11) |
3.69% | Details | |
| 1/7/2026 | Pfizer | PFE | New Coverage | Neutral (N/A) |
25.17 (28.55) |
13.43% | Details | |
| 1/6/2026 | Amgen | AMGN | New Coverage | Buy (N/A) |
320.72 (438.12) |
36.61% | Details |
